Silicone oil removal time extension possible for high-risk patients

Article

Silicone oil removal time could be increased for up to one year to achieve a stable retinal status in patients with high-risk redetachment.

Silicone oil removal time could be increased for up to one year to achieve a stable retinal status in patients with high-risk redetachment, states a paper in Eye.

A team headed by Dr Yasin Toklu, Department of Ophthalmology, Ankara Atatürk Training and Research Hospital, Ankara, Turkey, monitored 32 cases that were thought to have a high-risk of retinal redetachment after silicone oil removal.

The silicone oil was kept as long as possible until the first signs of silicone oil emulsification were identified. The silicone oil emulsification times varied between 5 and 24 months with a mean of 13.2 ± 4.8 months.

In the majority of cases, emulsification occurred within the first year, but two cases did not experience emulsification until the month 24.

The abstract can be read by visiting this link.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.